Harneys advises Maxpro Capital Acquisition Corp. on US$899 million SPAC acquisition with biopharmaceutical company Apollomics Inc.

Harneys has advised Maxpro Capital Acquisition Corp., a special purpose acquisition company (SPAC) on its US$899 million definitive agreement for a business combination with late-stage clinical biopharmaceutical company, Apollomics Inc. If approved, Apollomics will be publicly traded on Nasdaq Global Market under the ticker symbol "APML”.

Apollomics is an “innovative biotechnology company focussing on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer”. The transaction is predicted to close during early 2023.

The Harneys team was led by BVI based Partner George Weston, with support from Associate James Kitching. Harneys acted on instructions from US firm Nelson Mullins.

George commented: “We are delighted to have worked on this deal which further demonstrates our strength in the offshore SPAC sector.”

The Corporate team at Harneys excels at complex cross-border transactions involving BVI, Cayman Islands, Luxembourg and Cyprus vehicles. The firm’s significant track record includes complex mega-deals, high value private equity transactions, landmark IPOs and the full spectrum of public and private M&A and joint ventures. Our experienced SPAC practice group provides with Cayman and BVI incorporated vehicles with the full spectrum of legal advice and fiduciary services from incorporation, through to listing, business combination and beyond.